血清microRNA-375在非小细胞肺癌中的表达水平及其临床意义

The level and clinical significance of micro RNA-375 in serum of patients with non-small cell lung cancer

目的：探讨micro RNA-375（mi R-375）在非小细胞肺癌（non small-cell lung cancer,NSCLC）患者血清中的表达水平及临床意义。方法：采用实时荧光定量PCR方法检测82例非小细胞肺癌患者和对照组100例健康人血清的mi R-375的表达水平,分析其与临床病理参数之间的关系。结果：NSCLC组血清mi R-375表达水平显著低于对照组,并且其表达与临床分期和淋巴结转移有关（P〈0.05）。血清mi R-375在ROC曲线下面积（area under the ROC curve,AUC）为0.905（95%CI：0.860~0.950）。当血清mi R-375临界值取0.995时,对NSCLC诊断的灵敏度为92.0%,特异度为78.0%。结论：血清mi R-375可能作为一种新型NSCLC诊断的分子标志物和潜在的基因靶向治疗靶点。

Objective To investigate levels of microRNA-375 （miR-375） in the serum of patients with non-small cell lung cancer（NSCLC） and to determine whether there was a correlation between miR-375 level and clinical parameters. Methods Quantitative real-time PCR was used to measure the serum level of miR-375 in 82 patients with NSCLC and 100 healthy control subjects. The correlation between the serum miR-210 level and clinic opathological factors were investigated. Results The serum miR-375 was significantly decreased in patients with NSCLC. The level of miR-375 was significantly associated with the lymph node metastasis and clinical stage（P 〈 0.05）. The miR-375 yielded an area under the ROC curve （AUC） of 0.905 （95% CI： 0.860 ~ 0.950） and 92.0% and 78.0% of sensitivity and specificity, respectively. Conclusion The serum miR-375 level may be a novel diagnostic marker and a potential target for gene therapy for NSCLC.